Waverton Investment Management Ltd Acquires 98,933 Shares of Zoetis Inc. (NYSE:ZTS)

Waverton Investment Management Ltd lifted its stake in Zoetis Inc. (NYSE:ZTS) by 47.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 306,119 shares of the company’s stock after acquiring an additional 98,933 shares during the period. Zoetis accounts for about 1.0% of Waverton Investment Management Ltd’s investment portfolio, making the stock its 26th largest position. Waverton Investment Management Ltd owned approximately 0.07% of Zoetis worth $53,031,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Kornitzer Capital Management Inc. KS acquired a new position in Zoetis in the second quarter worth about $322,000. Deseret Mutual Benefit Administrators boosted its holdings in Zoetis by 17.6% during the second quarter. Deseret Mutual Benefit Administrators now owns 1,007 shares of the company’s stock worth $175,000 after buying an additional 151 shares during the last quarter. Mayflower Financial Advisors LLC raised its holdings in Zoetis by 2.2% in the second quarter. Mayflower Financial Advisors LLC now owns 4,809 shares of the company’s stock worth $834,000 after purchasing an additional 105 shares during the period. TD Asset Management Inc lifted its holdings in Zoetis by 5.9% during the second quarter. TD Asset Management Inc now owns 1,678,649 shares of the company’s stock worth $291,011,000 after acquiring an additional 93,239 shares in the last quarter. Finally, Commons Capital LLC grew its position in shares of Zoetis by 14.6% in the 2nd quarter. Commons Capital LLC now owns 6,485 shares of the company’s stock valued at $1,124,000 after purchasing an additional 825 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

ZTS opened at $186.59 on Friday. The firm has a 50-day moving average price of $180.90 and a 200-day moving average price of $174.57. The company has a market capitalization of $84.53 billion, a price-to-earnings ratio of 35.95, a PEG ratio of 2.87 and a beta of 0.88. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.41 EPS. Equities analysts expect that Zoetis Inc. will post 5.84 EPS for the current year.

Wall Street Analyst Weigh In

ZTS has been the topic of several research reports. Stifel Nicolaus restated a “buy” rating and issued a $200.00 target price on shares of Zoetis in a research note on Tuesday, August 27th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, BTIG Research boosted their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $217.11.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.